This Article Full Text Full Text (PDF) All Versions of this Article: 40/11/3641    most recent STROKEAHA.109.562231v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Meschia, J. F. PubMed PubMed Citation Articles by Meschia, J. F. Related Collections Secondary prevention Genomics Coumarins Genetics of Stroke Angioplasty and Stenting

(Stroke. 2009;40:3641.)
© 2009 American Heart Association, Inc.

Topical Review

Pharmacogenetics and Stroke

From the Mayo Clinic, Jacksonville, Fla.

Correspondence to James F. Meschia, MD, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224. E-mail meschia.james{at}mayo.edu

Martin Dichgans MD Robert A. Hegele MD, FRCPC, FACP Section Editors:

Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on genetic tests. Physicians, pharmaceutical companies, regulatory agencies, and health insurers continue to grapple with how best to translate this burgeoning field into effective individualized medicine.

Key Words: ischemic stroke • cerebral infarction • genetics • genomics • pharmacology • pharmacogenomics • prevention